Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation

Reference

• Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. [European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia.] Blood 1995;86:2041–50.
   Google Scholar
• Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555–62.
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261–8.
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Fromont C, Le Deist F et al. Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin. Transplantation 1990;50:1–7.
   Google Scholar
• Datta AR, Barrett AJ, Jiang YZ et al. Distinct T cell popula-tions distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant 1994;14:517–24.
   PubMed Web of Science ®Google Scholar
• Mavroudis DA, Jiang YZ, Hensel N et al. Specific depletion of alloreactivity against haplotype mismatched related indi-viduals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant 1996;17:793–9.
   PubMed Web of Science ®Google Scholar
• Koh MB, Prentice HG, Lowdell MW Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant 1999;23:1071–9.
   PubMed Web of Science ®Google Scholar
• van Dijk AM, Kessler FL, Stadhouders-Keet SA et al. Selective depletion of major and minor histocompatibility antigen reactive T cells: towards prevention of acute graft-versus-host disease. Br 7 Haematol 1999;107:169–75.
   PubMed Web of Science ®Google Scholar
• Rencher SD, Houston JA, Lockey TD, Hurwitz JL. Eliminating graft-versus-host potential from T cell immunotherapeutic populations. Bone Marrow Transplant 1996;18:415–20.
   PubMed Web of Science ®Google Scholar
• Mavroudis DA, Dermime S, Molldrem J et al. Specific depletion of alloreactive T cells in HLA-identical siblings: a method for separating graft-versus-host and graft-versus-leukaemia reations. Br y Haematol 1998;101:565–70.
   PubMed Web of Science ®Google Scholar
• Montagna D, Yvon E, Calcaterra V et al. Depletion of allore-active T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood 1999;93:3550–7.
   PubMed Web of Science ®Google Scholar
• Cavazzana-Calvo M, Stephan JL, Sarnacki S et al. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination. Blood 1994;83:2888–98.
   Google Scholar
• Harris DT, Sakiestewa D, Lyons C et al. Prevention of graft-versus-host disease (GvHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptor. Bone Marrow Transplant 1999;23:137–44.
   PubMed Web of Science ®Google Scholar
• Thorpe PE, Wallace PM, Knowles PP et al. Improved antitumor effects of immunotoxins prepared with deglyco-sylated ricin A-chain and hindered disulfide linkages. Cancer Res 1988;48:6396–403.
   PubMed Web of Science ®Google Scholar
• Schnell R, Vitetta E, Schindler J et al. Treatment of refrac-tory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. Leukemia 2000;14:129–35.
   PubMed Web of Science ®Google Scholar
• Kronke M, Schlick E, Waldmann TA et al. Selective killing of human T-Iymphotropic virus-I infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: potentiation by ammonium chloride and monensin. Cancer Res 1986;46:3295–8.
   Google Scholar
• Maino VC, Picker U. Identification of functional subsets by flow cytometry: intracellular detection of cytokine expres-sion Cytometry 1998;34:207–15.
   Google Scholar
• Johnson BD, Becker EE, Truitt RL. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Biol Blood Marrow Transplant 1999;5:123–32.
   Google Scholar
• Fowler DH, Kurasawa K, Smith R et all Donor CD4-enrichedcells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sub-lethally irradiated mice. Blood 1994;84:3540–9.
   PubMed Web of Science ®Google Scholar
• Fowler DH, Gress RE. CD8 T cells of Tc2 phenotype mediated a GVL effect and prevent marrow rejection. Vox Sang 1998;74(Suppl 2):331–40.
   Google Scholar
• Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo block-ade of CD28/CTLA4:B7/BB1 interaction with CT LA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barriers in mice. Blood 1994;83:3815–25.
   PubMed Web of Science ®Google Scholar
• Tiberghien P, Reynolds CW, Keller J et all Ganciclovir treat-ment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 1994;84:1333–41.
   PubMed Web of Science ®Google Scholar
• Bonini C, Ferrari G, Verzeletti S et all HSV-TK gene transferinto donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 199 7 ;276:1719-24.
   Google Scholar
• Hansen M, Ho C-K, Schaeffer A et al. Use of recipient-derived dendritic cells for identifying and removing alloreactive T cells from allografts. Blood 2000;96:33a.
   Google Scholar
• Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997;157:125–40.
   PubMed Web of Science ®Google Scholar
• Warren EH, Gavin M, Greenberg PD, Riddell SR. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr Opin Hematol 1998;5:429–33.
   PubMedGoogle Scholar
• Jiang YZ, Mavroudis DA, Dermime S et al. Preferential usage of T cell receptor (TCR) V beta by allogeneic T cells recognizing myeloid leukemia cells: implications for sepa-rating graft-versus-leukemia effect from graft-versus-host disease. Bone Marrow Transplant 1997;19:899–903.
   PubMed Web of Science ®Google Scholar
• Dolstra H, Fredrix H, Preijers F et al Recognition of a B cell leukemia-associated minor histocompatibility antigen by C T L. .7 immund 1997;158:560–5.
   PubMed Web of Science ®Google Scholar
• Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3239–41.
   Google Scholar
• Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. 7 Clin Oncol 1998;16: 2817–24.
   Google Scholar
• Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonma-lignant hematologic diseases. Blood 1998;91:756–63.
   PubMed Web of Science ®Google Scholar